Business
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET
Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nBroadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021\n\n\nInitiated RSVTx, a Phase 2b Study of EDP-938 in Adult Hematopoietic Cell Transplant Recipients with Acute Respiratory Syncytial Virus (RSV) Infection\n\n\nExpanded RSV Program with a Discovery Initiative for Novel RSV L-Protein Inhibitors\n\n\nRoyalty Revenue for the Quarter was $31.7 Million\n\n\nCash and Marketable Securities Totaled $404.7 Million at December 31, 2020\n\n\n WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2020.\n\n“Our first fiscal quarter of 2021 was an especially active time, as we advanced and expanded our wholly-owned pipeline. In HBV, not only did we advance our two ongoing Phase 1b trials of EDP-514, but we also broadened our program with the introduction of EDP-721, a novel HBV RNA destabilizer. We believe that an all-oral regimen of EDP-514, EDP-721 and a nucleos(t)ide reverse transcriptase inhibitor has the potential to lead to a functional cure. We anticipate having preliminary data in our two existing HBV trials in the second quarter of 2021, with a Phase 1 study of EDP-721 on track to initiate mid-year,” stated Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals.\n\n“We also made meaningful progress on our RSV franchise, initiating an RSV L-protein inhibitor discovery effort centered on potent nanomolar leads active against both RSV-A and RSV-B. Further, we initiated the Phase 2b RSVTx study evaluating EDP-938 in adult hematopoietic cell transplant recipients with RSV, and remain on track to initiate the Phase 2 RSVPEDs study of EDP-938 in pediatric patients with RSV this quarter. Meanwhile, we are in the process of expanding clinical sites for RSVP in Europe and Asia Pacific, so that we are ready when RSV re-emerges. Additionally, we are making significant progress in our discovery efforts in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19), with the goal of identifying two clinical candidates this year from among our hMPV, COVID-19 a...